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CC BY-NC-ND license (http://creativeAbstract Morbidly adherent placenta (MAP) is a growing concern currently and is still a diag-
nostic challenge for obstetricians. As emergency hysterectomy due to unscheduled delivery in
MAP carries significant risks, we aimed to evaluate whether first and second trimester serum
analytes may be used in the prediction of MAP requiring hysterectomy. A retrospective chart
review of all identified cases of placenta previa totalis with and without MAP was performed.
A total of 316 pregnant women diagnosed as placenta previa totalis were identified and included
in the analysis. Cases were examined in three groups (Group 1: 204 nonadherent placenta previa
patients; Group 2: 61 MAP patients managed with endouterine hemostatic square sutures and/
or Bakri balloon tamponade; and Group 3: 51 patients with MAP requiring hysterectomy). Among
all first and second trimester screening analytes only maternal serum alphafetoprotein (MS-AFP)
levels were significantly higher in patients with MAP requiring hysterectomy (p < 0.001). Ac-
cording to the Receiver Operating Characteristic (ROC) analysis performed for the predictive
value of MS-AFP levels, the area under the curve (AUC) was 0.742 [95% confidence interval
(CI): 0.505e0.979]. The best MS-AFP cut-off value was 1.25 multiple of the median (MoM) with
85.94% sensitivity and 71.43% specificity (p Z 0.036). The best predictors which affect the
increased risk of hysterectomy, was further evaluated by multivariate logistic regression ana-
lyses. Only elevated maternal serum alphafetoprotein (MS-AFP) was found to be an independent
predictor of MAP requiring hysterectomy [odds ratio (OR) Z 25.329, 95% confidence interval
(CI):1.487e43.143, p Z 0.025]. In conclusion, increased second trimester MS-AFP levels inde-
pendently predict morbidly adherent placenta requiring hysterectomy among women with
placenta previa totalis.
Copyright ª 2016, Kaohsiung Medical University. Published by Elsevier Taiwan LLC. This is an
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Morbidly adherent placenta (MAP) is a growing concern of
the current age, parallel to the increasing rate of cesarean
deliveries. It is defined as complete or partial invasion of
the chorionic villi into the myometrium and the incidence is
increased up to 1/533 pregnancies in the past few decades
[1,2]. Despite the improvements in imaging techniques such
as the use of high-resolution ultrasound and magnetic
resonance imaging, MAP is still a significant diagnostic
challenge for physicians [3,4]. As MAP has great potential of
life-threatening complications for both the mother and the
offspring, various studies investigated the possible risk
factors and predictive markers. The most important risk
factor proposed for MAP is prior cesarean deliveries in the
presence of placenta previa and other well-known risk
factors are: prior uterine surgery or curettage, advanced
maternal age, and multiparity [5,6]. The other entities
examined in predicting the possible abnormal invasion of
placenta are the maternal serum analytes used in first and
second trimester screening of aneuploidy. According to the
results of the previous reports, elevated maternal serum
alphafetoprotein (MS-AFP) and human chorionic gonado-
tropin (hCG) have a relation with the increased risk of
placenta accreta [7e10]. Besides, two recent retrospective
studies revealed increased levels of pregnancy-associated
plasma protein-A (PAPP-A) among women with placenta
accreta [11,12].
Morbidly adherent placenta carries significant risks for
pregnant women such as excessive hemorrhage, dissemi-
nated intravascular coagulopathy, ureteral/bladder/bowel
injury, need for hysterectomy, massive transfusion, and
even death [13]. The adverse outcomes associated with
MAP are not limited to the mother but also the offspring
may face a number of complications due to unscheduled
preterm delivery [13,14]. Considering the risks and adverse
outcomes among patients with MAP, the significance of the
condition and the need for early diagnosis become more
apparent. Besides, the greatest risk to a patient with
abnormal invasion is probably when an emergency hyster-
ectomy is required [15]. Therefore, strategies to enhance
the antenatal diagnosis should be developed and if
abnormal invasion is suspected in pregnant women, they
should be directed to a tertiary center as the management
of MAP requires a multidisciplinary approach and an expe-
rienced team also [4,13].
Thus we aimed to evaluate whether first and second
trimester serum analytes may be used in the prediction of
MAP requiring hysterectomy. Our second objective was to
evaluate the outcomes of pregnancies with MAP managed in
a tertiary referral hospital.
Materials and methods
A retrospective chart review of all identified cases of
placenta previa totalis with and without MAP delivered at
Perinatology Department of Zekai Tahir Burak Women’s
Health Education and Research Hospital, Ankara, Turkey
between 2009 and 2015, was performed. The study protocol
was approved by the Institutional Review Board of our
hospital.Only cases with available both first and second trimester
screening tests for aneuploidy and delivered in our hospital
were included into the study. The medical records of all
participants were reviewed to collect demographic and
anthropometric data, obstetric, medical and family history,
and maternal and neonatal outcomes of the current preg-
nancy. Patients were excluded if any of the following dis-
orders were present: multiple pregnancy, fetal chromosomal
abnormalities, previous pregnancy complicated with
placenta previa, prior cervical or uterine surgery other than
cesarean section and curettage, pregnancies achieved by
artificial reproductive technology, any known systemic dis-
ease, cigarette and alcohol consumption, and patients using
medication. Patients with fetal and placental abnormalities
(other than placenta accreta) that may be associated with
elevated MS-AFP levels such as: fetal neural tube defects,
abdominal wall defects, gastrointestinal, renal, dermato-
logical, and skeletal system abnormalities, and placental
chorangioma or abruption were also excluded.
All participants included in the study were delivered by
cesarean section (C-section) with the indication of placenta
previa totalis. The reasons for previous C-sections based on
the participant declarations were the malpresentation of
the fetus, cephalopelvic disproportion, previous history of
C-section, and fetal distress during the course of vaginal
delivery.
The operative information were examined carefully for
the type of procedure used, location of the placenta, de-
gree of invasion of uterine wall and adjacent organs, and
intra operative complications. All cases with MAP requiring
hysterectomy were histologically confirmed according to
previously established criteria as the abnormal adherence
of placenta involving all degrees to the underlying uterine
wall [16]. In conservatively managed MAP patients the
diagnosis was based upon the operative records as the
difficult manual removal with no cleavage plane identified
between the placenta and uterus, resulting in incomplete
removal and/or heavy bleeding from implantation site after
placental removal during cesarean section [9,17].
The number of packed red blood cells (PRBC), fresh frozen
plasma (FFP), and other blood products transfused were all
obtained from postoperative records. All maternal and fetal
outcomes were recorded including the data of admission to
both adult and neonatal intensive care units (ICU).
Maternal serum analytes included were: first trimester
PAPP-A and free beta human chorionic gonadotropin,
collected between 11 weeks 0 days and 13 weeks 6 days
gestation, and second trimester MS-AFP, hCG, unconjugated
estriol (uE3) collected between 16weeks 0 days and 20weeks
0 days gestation. All analytes were measured on automated
equipment IMMULITE 2000 (Siemens Healthcare Diagnostics,
Los Angeles, CA, USA) solid-phase competitive chemilumi-
nescent enzyme immunoassay system as per the manufac-
turer’s instructions. All analytemultiple of the median (MoM)
values were adjusted for gestational age, maternal weight,
race/ethnicity, smoking status, and preexisting diabetes.Statistical analysis
IBM SPSS Statistics for Windows, version 17.0 (SPSS Inc.,
Chicago, IL, USA) was used for statistical analysis. Data were
Table 1 Anthropometric and clinical characteristics of the groups.
Group 1
(Placenta previa
totalis)
n Z 204
Group 2
MAP-managed
conservatively
n Z 61
Group 3
MAP-requiring
hysterectomy
n Z 51
p* p**
Age (y) 37.71  5.68 34.01  6.09 34.23  4.66 p(ab) Z 0.05 0.001
p(ac) Z 0.04
p(bc) Z NS
BMI (kg/m2) 27.96  3.37 27.15  4.64 27.32  3.24 P(ab) Z NS 0.176
P(ac) Z NS
P(bc) Z NS
Gravidity 2.63  1.42 3.40  1.94 3.52  1.39 p(ab) Z 0.001 < 0.001
p(ac) < 0.001
p(bc) Z NS
Parity Nulliparous 65 (32) 10 (16.4) 3 (5.88) < 0.001
Multiparous 138 (68) 51 (83.6) 48 (94.12)
Previous curettage 38/204 (18.62) 16/61 (27.8) 9/51 (17.64) 0.314
Previous pregnancy
outcome
1st pregnancy 50 (24.5) 6 (9.8) 2 (3.9) < 0.001
vaginal 52 (25.49) 6 (9.8) 0
Cesarean 61 (29.90) 40 (65.6) 48 (94.1)
Abortion 6 (2.94) 0 0
Curettage 34 (16.67) 9 (14.8) 1 (2.0)
Birth wk 35.25  4.14 34.38  3.72 34.01  3.98 p(ab) Z NS 0.086
p(ac) Z NS
p(bc) Z NS
Management Hysterectomy 0 0 51 (100) <0.001
Bakri balloon
tamponade &/or
square suture
9 (4.3) 50 (82.0) 0
Birth weight (kg) 2781.28  742.17 2514.66  779.92 2587.45  814.89 p(ab) Z 0.018 0.033
p(ac) Z NS
p(bc) Z NS
NICU admission 22 (10.78) 18 (29.50) 15 (29.41) 0.001
AICU admission 58 (28.43) 61 (100) 51 (100) < 0.001
Blood transfusion 62 (30.39) 61 (100) 51 (100) < 0.001
Erythrocyte suspension (ES) 2.29  1.12 3.88  1.69 8.22  2.83 p(ab) < 0.001 < 0.001
p(ac) < 0.001
p(bc) < 0.001
Fresh frozen plasma (FFP) 2.77  1.73 3.25  1.44 6.55  2.33 p(ab) Z NS < 0.001
p(ac) < 0.001
p(bc) < 0.001
Data are presented as n (%), n/N (%), or mean  standard deviation.
* p value Z within two groups.
** p value Z between all groups; p < 0.05 is statistically significant.
AICU Z adult intensive care unit; BMI Z body mass index; MAP Z morbidly adherent placenta; NICU Z neonatal intensive care unit;
NS Z Not significant.
MS-AFP in prediction of MAP requiring hysterectomy 581presented as mean  standard deviation or median (min-
emax) and percentages (%). Degrees of association between
variables were evaluated after adjustment for age. Contin-
uous variables were tested for normality by the Kolmogor-
oveSmirnov test. Categorical comparisons were performed
using theChi-square test.Weused the independent samples t
test and ManneWhitney U test for parametric and nonpara-
metric groups respectively. The optimal cut-off points of
laboratory measurements to discriminate cases with and
without MAP were evaluated by Receiver Operating Charac-
teristic (ROC) analyses calculating area under the curve
(AUC) as giving the maximum sum of sensitivity and speci-
ficity. Multiple logistic regression analysis was performedfor the determination of the best predictors for the need of
hysterectomy among placenta previa patients. Any variable
whoseunivariable test had a p value< 0.05was accepted as a
candidate for the multivariable model along with all vari-
ables of known clinical importance. Adjusted OR and 95% CI
were calculated for each variable. A p value < 0.05 was
considered to be statistically significant.Results
A total of 316 pregnant women diagnosed as placenta
previa totalis were identified and included in the analysis.
Table 2 First and second trimester maternal serum analytes compared between groups.
Group 1
(Placenta previa totalis)
n Z 204
Group 2
(MAP-managed
conservatively)
n Z 61
Group 3
(MAP-requiring
hysterectomy)
n Z 51
p* p**
PAPP-A (MoM) 1.01  0.96 1.19  0.80 1.75  1.41 P(ab) Z NS 0.262
P(ac) Z NS
P(bc) Z NS
free bhCG (MoM) 1.21  0.82 1.11  0.62 1.46  1.02 P(ab) Z NS 0.686
P(ac) Z NS
P(bc) Z NS
uE3 (MoM) 0.88  0.34 0.96  0.50 1.10  0.49 P(ab) Z NS 0.381
P(ac) Z NS
P(bc) Z NS
hCG (MoM) 1.13  0.48 1.39  0.85 1.19  0.56 P(ab) Z NS 0.344
P(ac) Z NS
P(bc) Z NS
AFP (MoM)* 0.87  0.37 1.18  0.16 1.28  1.065 P(ab) Z NS < 0.001
P(ac)< 0.001
P(bc) [ 0.007
Data are presented as mean  standard deviation.
* p value Z within two groups.
** p value Z between all groups; p < 0.05 is statistically significant.
AFPZ alphafetoprotein; free bhCGZ free beta human chorionic gonadotropin; hCGZ human chorionic gonadotropin; MoMZ multiple
of the median; PAPP-A Z pregnancy-associated plasma protein-A; uE3 Z unconjugated estriol.
The bold characters point out the statistically significant p values.
582 E. Oztas et al.Cases were examined in three groups (Group 1: 204 non-
adherent placenta previa patients, Group 2: 61 MAP pa-
tients managed with endouterine hemostatic square
sutures and/or Bakri balloon tamponade or medically, andFigure 1. Area under the receiver operating characteristic
curve (AUC) for maternal serum AFP levels in predicting
morbidly adherent placenta requiring hysterectomy. The AUC
was 0.742 (95%CI: 0.505e0.979). The best MS-AFP cut-off value
was 1.25 MoM with 85.94% sensitivity and 71.43% specificity
(p Z 0.036). AFP Z alphafetoprotein; MoM Z multiple of the
median; MS-AFP Z maternal serum alphafetoprotein.Group 3: 51 patients with MAP requiring hysterectomy). The
demographic and clinical characteristics of all groups are
given on Table 1. Women with MAP (both Groups 2 and 3)
were significantly younger than the ones with nonadherent
placenta previa group (p Z 0.001). So, further statistical
analysis was performed after adjustment for age. There
were no statistically significant differences among body
mass index (BMI), previous number of curettages, and birth
week between groups. The majority of women in Groups 2
and 3 were multiparous with the highest percentage of
prior Cesarean deliveries in Group 3 (p < 0.001). Group 3
only consisted of patients managed with hysterectomy. In
36 out of 51 patients (70.5%) in Group 3 abnormal invasion
was suspected according to the preoperative ultrasono-
graphic findings. These patients were multiparous and
managed with planned cesarean hysterectomy and the
operation was performed by midline incision after written
informed consents were provided. In the rest of the pa-
tients in Group 3, hysterectomy was decided intra-
operatively if the placenta was evidently invaded through
the uterine serosa or if the bleeding could not be controlled
by conservative management. Bakri balloon tamponade
and/or endouterine hemostatic square sutures were used in
nine patients (4.3%) in Group 1 and in 50 (82.0%) patients in
Group 2 for the management of hemorrhage. For the rest of
the patients medical therapy was sufficient in the man-
agement of bleeding (Table 1).
The need of blood transfusion was 30.39% in Group 1,
while all women with MAP (Groups 2 and 3) required
transfusion. The number of transfused PRBC (mean  SD,
8.22  2.83) and FFP (mean  SD, 6.55  2.33) units were
highest in Group 3 when compared with both Groups 1 and 2
(p < 0.001). All women with MAP (100%) and 58 women with
nonadherent placenta previa (28.43%) were followed in
Table 3 Multivariate logistic regression analysis of several factors in the prediction of morbidly adherent placenta requiring
hysterectomy among all placenta previa totalis patients.
Univariate analysis Multivariate analysis
Odds ratio (95%Cl) p* Odds ratio (95%Cl) p*
Age (y) 1.066 (1.009e1.126) 0.024 0.948 (0.809e1.111) 0.508
Previous cesarean ( 1) 0.039 (0.012e0.128) < 0.001 0.110 (0.009e1.308) 0.081
Previous curettage ( 1) 9.773 (1.314e72.665) 0.026 1.661 (0.040e68.918) 0.790
PAPP-A (MoM) 1.526 (0.834e2.790) 0.170
free bhCG (MoM) 1.460 (0.618e3.449) 0.338
uE3 (MoM) 2.927 (0.521e16.427) 0.222
hCG (MoM) 1.252 (0.261e6.010) 0.778
AFP (MoM)* 7.011 (1.223e 40.202) 0.029 25.329 (1.487e43.143) 0.025
* p < 0.05 is statistically significant.
AFP Z alphafetoprotein; CI Z confidence interval; free bhCG Z free beta human chorionic gonadotropin; hCG Z human chorionic
gonadotropin; MoM Z multiple of the median; PAPP-A Z pregnancy-associated plasma protein-A; uE3 Z unconjugated estriol.
The bold characters point out the statistically significant p values.
MS-AFP in prediction of MAP requiring hysterectomy 583intensive care unit (ICU) postoperatively. Bladder injury
rate noted was 17.65% (n Z 9), in only patients who un-
derwent hysterectomy. There were no maternal or
neonatal deaths. The need for admission to neonatal ICU
were significantly higher in Groups 2 and 3 [18 neonates in
Group 2 (29.50%) and 15 neonates in Group 3 (29.41%)]
when compared with Group 1 (p Z 0.001; Table 1).
Maternal serum analyte values are shown in Table 2.
Among all first and second trimester screening analytes only
MS-AFP levels were significantly higher in Group 3
(mean  SD, 1.28  1.065 MoM) when compared with Group
2 (p Z 0.007) and Group 1 (p < 0.001; Table 2).
The optimal cut-off point for second trimester MS-AFP
for the prediction of MAP requiring hysterectomy, was
further evaluated by ROC analyses by calculating AUC as
giving the maximum sum of sensitivity and specificity for
the significant test. According to the ROC analysis per-
formed for the predictive value of MS-AFP levels, the AUC
was 0.742 (95% CI: 0.505e0.979). The best MS-AFP cut-off
value was 1.25 MoM with 85.94% sensitivity and 71.43%
specificity (p Z 0.036; Figure 1).
The best predictors which affect the increased risk of
hysterectomy, was evaluated by multivariate logistic
regression analyses. Any variable whose univariable test
had a p value < 0.05 was accepted as a candidate for the
multivariable model along with all variables of known
clinical importance. Only elevated MS-AFP was found to be
an independent predictor of MAP requiring hysterectomy
(OR Z 25.329, 95% CI: 1.487e43.143, p Z 0.025; Table 3).
Discussion
In the present retrospective analysis we found that among
pregnant women with placenta previa totalis, second
trimester MS-AFP levels > 1.25 MoM were independently
predictive for MAP requiring hysterectomy.
AFP is a glycoprotein comprising an a-globulin of 591
amino acids and a carbohydrate moiety and it exists in
monomeric form with a molecular weight of 67 kDa [18,19].
AFP is the principal serum binding protein in the fetus, and
have an important role of carrying hormones, fatty acids,
bilirubin, and minerals across the maternalefetal interface[19]. It is synthesized by the yolk sac during early preg-
nancy, and later by the fetal gastrointestinal tract and
liver, which is the main source throughout the rest of the
pregnancy [20]. After synthesized AFP is excreted by fetal
urine and transported to maternal serum through the
placenta or by diffusion across fetal membranes [21].
Second trimester elevated MS-AFP levels are known to
be associated with various fetal and placental pathologies.
The most common associated fetal structural abnormality is
neural tube defects, and others are ventral wall defects,
gastrointestinal, renal, skeletal, and skin abnormalities. In
our study, all records of the patients including the data of
the neonates were examined and the patients with possible
or proven fetal structural and/or chromosomal anomalies
were all excluded. Placental pathologies such as chor-
angioma may also cause elevated MS-SFP levels and previ-
ous reports suggested that increased MS-AFP levels in a
structurally normal fetus may be a consequence of a
disruption of the maternalefetaleplacental barrier,
placental vascular damage, fetomaternal bleeding, or
placental ischemia [22e25]. In our hospital histopathologic
examination of all placental specimens are routinely per-
formed in previa cases. We also excluded the patients with
placental pathologies that might be associated with
elevated MS-AFP levels. As a result, our results indicate a
significant relation between elevated second trimester MS-
AFP levels and MAP leading to cesarean hysterectomy. This
relation has a clinical significance especially in patients
with elevated second trimester MS-AFP levels that cannot
be explained with other fetal or placental pathologies.
The other group of patients with MAP managed success-
fully by conservative surgical strategies (Group 2) had also
increased MS-AFP levels when compared with the previa
only group (Group 1) but the difference was not statistically
significant. Only the significantly elevated levels of MS-AFP
were observed when hysterectomy required MAP patients
were compared with both of the other two groups. Based on
the information given by the above mentioned studies we
suggest that this might be due to the disruption of the
maternalefetal interface and our results showed that the
greater breakdown of the maternalefetal interface may
cause more increased levels of MS-AFP.
584 E. Oztas et al.Our results are consistent with the previous studies indi-
cating that elevated second trimester MS-AFP levels are
associated with MAP among women with placenta previa
[7e9,12]. However, they particularly evaluated the associa-
tion of significantly elevatedMS-AFP levels (> 2.5MoM, higher
than the cut-off value for the upper limit of normal in second
trimester screening) and suggested that this value canbeused
to predict the occurrence of placenta accreta [8e10]. This
may seem to be inconsistent with the results of the present
studyaswe foundacut-off value forMS-AFPas1.25MoM in the
prediction of MAP requiring hysterectomy. But previous
studies although showed that MS-AFP > 2.5 MoM can predict
placenta accreta, they also indicated that in most cases MS-
AFP levels were  2.5 MoM as in the study of Dreux et al.
[10]. They suggested increased risk for accreta in patients
with MS-AFP> 2.5 MoM but also demonstrated that the mean
valueofMS-AFPwas1.23MoMamongall accreta patients [10].
Also, Hung et al. [9] reported a similar result, asMS-AFP levels
were ranging between 0.5 MoM and 2.5 MoM in themajority of
(89%) accreta patients. Therefore,we still suggest the clinical
significance of even mildly elevated MS-AFP levels in the
prediction of MAP in placenta previa patients.
Previous studies also suggested a relation between first
trimester elevated PAPP-A levels and increased risk of MAP
[11,12]. It may seem contradictory to the results of the
present study as we did not find such a relation. However, it
is clear that there is an evident but not significant increase
in PAPP-A levels, in patients with MAP requiring hysterec-
tomy in our study. So PAPP-A levels tended to increase but
failed to reach a statistically significant level probably due
to the limited number of patients in the present study.
Considering the adverse outcomes of MAP, our results are
again consistent with the previous studies with an increased
need of transfusion and ICU admission and also operational
morbidities such as adjacent organ injuries and postoperative
bleeding [14,26,27]. Therefore, it is evident that the suc-
cessful management of MAP depends on an accurate preop-
erative diagnosis and subsequent delivery of the patient to a
tertiary center which can be managed by an experienced
team inorder toavoidorminimize thepossiblecomplications.
The major limitations and confounding issues are the
retrospective design of the present study and the limited
number of participants in each group. Also some con-
founding factors such as parity, first pregnancy, and vaginal
delivery were not appropriately controlled among groups,
and this is also a significant limitation. However, previous
cesarean and curettage history were evaluated with
multivariate regression analysis but revealed no significant
role in the prediction of MAP requiring hysterectomy among
placenta previa totalis patients.
In conclusion we suggest that increased second trimester
MS-AFP levels independently predict morbidly adherent
placenta requiring hysterectomy among women with
placenta previa totalis. Further prospective studies with a
larger study population are needed to validate the results
of the present study.References
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